Psychiatric diagnosis

Caregivers Helping Caregivers: New Web Resource for Helping a Loved One with Day-to-Day Activities

Retrieved on: 
Wednesday, August 4, 2021
Health, Caregiving, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Activities of daily living, Occupational therapy, Caregiver, Family caregivers, Dementia, Alzheimer's disease

When you add in helping their loved one with many of their day-to-day activities, it can become overwhelming.

Key Points: 
  • When you add in helping their loved one with many of their day-to-day activities, it can become overwhelming.
  • Most family caregivers need to assist their loved ones with activities of daily living (ADLs)eating, bathing/showering, dressing, mobility, and using the toilet.
  • For someone caring for a loved one with Alzheimers disease or other forms of dementia, assisting with these types of activities may be happening more often.
  • Caregivers have an opportunity to share their own story and how they have managed these day-to-day activities.

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer’s Pursuant to the Securities Purchase Agreement with Digital Power Lending

Retrieved on: 
Wednesday, August 4, 2021
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Psychiatry, Psychiatric diagnosis, Branches of biology, Cognitive disorders, Learning disabilities, Neuroscience, Dementia, Aging-associated diseases, Alzheimer's disease, Geriatric psychology

Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments.

Key Points: 
  • Dementia is not a normal part of aging, and there are numerous symptoms that can indicate cognitive and neurological impairments.
  • Over 47 million people in the world currently live with Alzheimers disease or dementia, with over 6.2 million in the U.S. (two-thirds are women).
  • According to the Alzheimers Association, it is estimated that Alzheimers and dementia deaths increased more than 16% in 2021 due to COVID-19.
  • More information, including potential risk factors, that could affect Alzamends business and financial results are included in Alzamends filings with the U.S. Securities and Exchange Commission.

Caravel Autism Health Opens Another Wisconsin Center for Children with Autism

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Psychiatric diagnosis, Psychiatry, Abnormal psychology, Autism, Pervasive developmental disorders, Global perceptions of autism, Autism Speaks

KENOSHA, Wis., Aug. 4, 2021 /PRNewswire/ -- Caravel Autism Health , a leader in the diagnosis and treatment of children on the autism spectrum, has just opened a new center in Kenosha, WI.

Key Points: 
  • KENOSHA, Wis., Aug. 4, 2021 /PRNewswire/ -- Caravel Autism Health , a leader in the diagnosis and treatment of children on the autism spectrum, has just opened a new center in Kenosha, WI.
  • Caravel Autism Health was founded in Green Bay in 2009 by clinicians who specialize in treating childhood autism.
  • "Caravel Autism Health wants to expand access to the best possible care for children who have autism," said Mike Miller, Caravel's Chief Executive Officer.
  • Since 2009, Caravel Autism Health has been devoted to helping families navigate the challenges of childhood autism.

Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Biology, Psychiatric diagnosis, Neurodegenerative disorders, Neurodegeneration, Neuroscience, Senescence, Alzheimer's disease, Parkinson's disease

The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's.

Key Points: 
  • The composition of matter patent secures exclusivity for a new group of iron chaperones designed to redistribute the excess iron implicated in many neurodegenerative diseases, including Alzheimer's and Parkinson's.
  • The patent, entitled "Compounds for and Methods of Treating Diseases", covers more than80 novel compounds and underwent prioritized examination by the USPTO.Together with the recent grant of Alterity's US patent No.
  • This position was further exemplified by the absence of any novelty or inventiveness objections during the course of prosecution.
  • Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people livingwith neurodegenerative diseases.

Diadem Awarded Patent in China for Its AlzoSure® Prognostic Biomarker Technology that Accurately Predicts Progression to Alzheimer's Disease

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Psychiatry, Alzheimer's disease, Dementia, Eponyms

The patent, which covers key elements of the technology and testing protocol, provides protection through 2035.

Key Points: 
  • The patent, which covers key elements of the technology and testing protocol, provides protection through 2035.
  • "According to the Chinese Geriatrics Society, the number of Alzheimer's patients in China is expected toexceed 40 million by 2050.
  • Early identification has never been more important as interventions to slow or halt disease progression are now becoming available.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

Global Bipolar Depression Market Insight, Epidemiology and Market Forecast 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical, Health, Mental health, Psychiatric diagnosis, Psychiatry, Mind, Psychology, Mood disorders, Depression, Mood stabilizers, Bipolar spectrum, Bipolar disorder, Bipolar I disorder, Major depressive disorder, Lurasidone

The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bipolar Depression - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Bipolar Depression - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The Bipolar Depression epidemiology division provides insights about the historical and current Bipolar Depression patient pool and forecasted trends for every seven major countries.
  • In 2013, lurasidone was approved as a monotherapy and adjunct to ongoing lithium or valproate for bipolar I depression.

Health and Technology Company, Bright™, Launches to Develop a Cognitive Decline Solution Through Passive and Active Wellness Routines!

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Psychiatry, Mind, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Dementia, Neuroscientist, Alzheimer's disease

NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Co-Founders Irina Tanenbaum, Wendy Bronfin and Veronica Price announce the launch of BRIGHT, the health and technology company that fast-tracks scientific research to create passive therapies and active wellness routines for cognitive health.

Key Points: 
  • NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Co-Founders Irina Tanenbaum, Wendy Bronfin and Veronica Price announce the launch of BRIGHT, the health and technology company that fast-tracks scientific research to create passive therapies and active wellness routines for cognitive health.
  • The company's core products combine technology with behavior and biology, to encourage brain health and wellness.
  • A noninvasive and unobtrusive treatment, 40Hz light can help promote brain health for people living with Alzheimer's disease symptoms as well as those who are looking to prevent cognitive decline.
  • Veronica, a neurobiologist, brings 20+ years of diverse business experience in start-ups, corporations, and nonprofits to the BRIGHT team.

OraVital Launches 'Are You Kissable' Campaign To Bring Awareness To How Gum Disease Spreads

Retrieved on: 
Monday, August 2, 2021
Medical specialties, Branches of biology, Mouth, Periodontology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Periodontal disease, Chewing gum, Alzheimer's disease, Gums

campaign with the aim of bringing awareness to people across all demographics, to the dangers of having gum disease and kissing loved ones.

Key Points: 
  • campaign with the aim of bringing awareness to people across all demographics, to the dangers of having gum disease and kissing loved ones.
  • It's time to stop the bleeding with a new approach to treating gum disease."
  • This can go on for decades and cause an array of systemic diseases such as atherosclerosis, Alzheimer's and even cancers."
  • The message is meant to bring awareness to the dangers of gum disease, the danger of passing it to loved ones, and to get people interested in referring their dental clinic to consider the OraVital System which has been specially formulated to stop the progression of gum disease in its tracks.

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of Symptomatic Frontotemporal Dementia Patients with a Progranulin Mutation

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Psychiatry, Cognitive disorders, Psychiatric diagnosis, Neuroscience, Dementia, Frontal lobe, Temporal lobe, Frontotemporal dementia, Granulin

DENVER, July 29, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, presented promising results from the company’s INFRONT-2 Phase 2 clinical trial of AL001 at the Alzheimer’s Association International Conference (AAIC 2021). AL001 is initially being developed for the treatment of adults at risk for or with symptomatic frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). AL001 is a potential first-in-class monoclonal antibody designed to elevate progranulin, a key regulator of immune activity in the brain. Decreased progranulin levels due to genetic mutations are a known cause of frontotemporal dementia (FTD), a rare, rapidly progressing neurodegenerative disease that is the most common form of dementia for people under the age of 60.

Key Points: 
  • Treatment with AL001 showed a 47% slowing of clinical progression among the INFRONT-2 patients relative to matched GENFI2 controls.
  • In contrast, the annual increase in the AL001 cohort (N=12) was only 3.4 points over one year, a 3.0-point difference in annual change.
  • Alector management will host a conference call to review and discuss data presented at AAIC 2021 today at 1:00 p.m.
  • There are multiple heritable forms of frontotemporal dementia, and FTD-GRN patients represent 5% to 10% of all people with FTD.

Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Significantly Prevented Aβ (Abeta)-induced Cognitive Deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer’s Disease

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Biology, Clinical medicine, Psychiatric diagnosis, Learning disabilities, Amyloidosis, Cognitive disorders, Biomarkers, Dementia, Amyloid beta, Rett syndrome, Alzheimer's disease

NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today reported new data that established ANAVEX®2-73 to be a preventive treatment in the pharmacological model of Alzheimer's disease (AD). Pre-treatment with ANAVEX®2-73, repeated once daily for one week before the Aβ (Abeta) challenge was protective in the Aβ25-35 peptide model of Alzheimer’s disease in mice. ANAVEX®2-73 significantly and dose-dependently prevented Aβ25-35-induced biomarker-correlated cognitive impairments, which were assessed one week after the Aβ (Abeta) insult during which no further ANAVEX®2-73 treatment took place.

Key Points: 
  • Pre-treatment with ANAVEX2-73, repeated once daily for one week before the A (Abeta) challenge was protective in the A25-35 peptide model of Alzheimers disease in mice.
  • ANAVEX2-73 significantly and dose-dependently prevented A25-35-induced biomarker-correlated cognitive impairments, which were assessed one week after the A (Abeta) insult during which no further ANAVEX2-73 treatment took place.
  • In these same patients, ANAVEX2-73 also improved ADCS-ADL, by +6.0 points, an 8% mean improvement from baseline to 70 weeks.
  • Anavex Life Sciences product portfolio platform includes orally available small molecule drug lead candidate ANAVEX2-73 for the treatment of Alzheimers disease, Parkinsons disease and Rett syndrome and ANAVEX3-71 for frontotemporal dementia.